About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

August 21, 2014

Non Regulatory

The Oasmia Pharmaceutiacal Annual Report is now published

The Oasmia Annual Report for the fiscal year 2013/2014 is now available at the company website www.vivesto.com.

Documents

annual_report_oasmia_2014

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Media

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a research and development company that develops new treatment options for patients suffering from hard-to-treat cancer. The company develops projects with the potential to offer new treatment options for cancer patients with high medical needs. Vivesto has the capacity and expertise to develop drugs from early preclinical development to clinical phase. Late clinical-phase and commercial development is intended to take place through partnerships with other pharmaceutical companies.

Vivesto is developing the cancer programs Cantrixil and Docetaxel micellar, and the veterinary oncology program Paccal Vet (paclitaxel micellar) which is being developed for the treatment of malignant melanoma and hemangiosarcoma in dogs.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com